**Use Your Power for Purpose**
The US Commercial organization, which is in the Global Hospital & Biosimilars organization, is comprised of over 200 products, spanning more than 10 therapeutic areas, with annual revenue of over $2.5B. The US Commercial Biosimilars Portfolio is comprised of the combined Inflammation & Immunology (I&I) and Oncology biosimilars (BSM) portfolios, with net revenue of ~$0.9B, within the US Commercial organization. This includes eight BSM assets - ...